長時間作用型注射劑市場

Long-Acting Injectable Drugs

出版日期: 2022年07月31日 | 出版商:

Greystone Research Associates | 英文 | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本報告提供全球長時間作用型注射劑市場相關調查，市場概要，以及製劑技術概要，向治療領域，及市場參與市場企業的競爭趨勢等資訊。

生物分解性聚合物
PEG
PLA/PLGA
聚醚酯
長時間作用型注射劑
- 製劑技術
BEPO (MedinCell)
ChroniJect (Oakwood Laboratories/PharmaSophia)
CriticalMix (Critical Pharmaceuticals)
Depofoam (Pacira)
FluidCrystal (Camarus)
LinkeRx (Alkermes)
Medisorb (Alkermes)
Medusa (Recipharm/Avadel)
Nanocrystals (Alkermes)
Optisomes (Talon/Spectrum)
PolyActive (Octoplus)
Q-Sphera (Midatech Pharma)
SABER/SAIB (DURECT)
SynBiosys (Innocore)
TransCon (Ascendis)

物理的流程管理方法

長時間作用型注射劑- 開發要素

配合要素
穩定
管理要素

長時間作用型產品的分析

治療部門分析

中毒
血糖控制
感染疾病
肝炎
神經學
思覺失調症
躁鬱症
腫瘤
疼痛管理
生殖醫療
不孕
子宮內膜異位症

企業簡介

簡介目錄

Product Code: LAJD777K

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

What You Will Learn:

What are the marketed long-acting injectable drug products, what long-acting formulation technologies are used, and who markets them?

What are the major factors driving long-acting injectable drug demand?

What long-acting injectable drug candidates are in late-stage clinical development and what is their potential impact?

How important are drug developer-formulation technologist relationships in the long-acting market segment, and what are the key alliances in the industry?

What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for long-acting injectable drug products?

In what therapeutic market segments do long-acting injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?